US09076W1099
© BusinessWire
07.01.2026
BIAF
LISTED
NASDAQ
bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that its wholly owned laboratory subsidiary, Precision Pathology Laboratory Services (PPLS), has successfully maintained its accreditation from the College of American Pathologists (CAP) follo...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster at the American Cancer Society National Lung Cancer Roundtable (NLCRT) showcasing three cases in which CyPa...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Reports Third Quarter 2025 Financial Results
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2025.
Key Highlights
CyPath® Lung revenues increased 86% year over year for the first n...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
28.10.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics including CyPath® Lung, the Company’s noninvasive test for lung cancer, today announced that the Australian Patent Office (IP Australia) has accepted a patent application for the Company’s proprietary platform technology for assessing lu...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
20.10.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced it will present research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The study supports the methods used to collect and transport patient samples...
Themefolio
Profiler
Peergroup
© BusinessWire
16.10.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced it has received a notification of allowance from the United States Patent and Trademark Office (USPTO) for a new patent...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced that it has received a written notice from The Nasdaq Stock Market LLC stating that the Company has regained compliance...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2025
BIAF
LISTED
NASDAQ
WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
News Preview
JERSEY CITY, N.J., Oct. 9, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of earl...
Themefolio
Profiler
Peergroup
© BusinessWire
09.10.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the previously announced definitive agreements for the purchase and sale of 720,000 shares of common stock at a purchase price of $2.50 per share in a register...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into definitive agreements for the purchase and sale of 720,000 shares of common stock, par value $0.007 per share, at a purchase price of $2.50 per sha...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced sales of its CyPath® Lung diagnostic test for lung cancer reached a new high in the third quarter of 2025, representing a 95% increase over the previous quarter. The increase refle...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
BIAF
LISTED
NASDAQ
WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
News Preview
JERSEY CITY, N.J., Sept. 30, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
30.09.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $4.8 million, before deducting agent...
Themefolio
Profiler
Peergroup
© BusinessWire
29.09.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a public offering of securities as described below for aggregate gross proceeds to the Company of $4.8 million, before deducting agent fees and other esti...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released three additional case studies – one in which use of CyPath® Lung led to detecting lung cancer at Stage 1A, its earliest and possibly curative stage, and two where risky invasive pro...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-30 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on September 19, 2025, the Company’s c...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
BIAF
LISTED
NASDAQ
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released another compelling case study in which its flagship product, CyPath® Lung, identified cancer in a patient with an incidental finding of ground-glass lung nodules.
Ground-glass nod...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2025
BIAF
LISTED
NASDAQ
U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
News Preview
U.S. Medicine, a leading publication for federal healthcare professionals, has featured bioAffinity Technologies’ CyPath® Lung in its pulmonary issue, highlighting the test’s potential to improve lung cancer detection while lowering costs for the Department of Veterans Affairs (VA).
“We are honored that U.S. Medicine recognized both the economic...
Themefolio
Profiler
Peergroup
© BusinessWire
18.08.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Appoints New Members to Board of Directors
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors.
“Mr. Rios’ business and financial expertise combined with Dr. Op...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its previously announced private placement transaction for the purchase and sale of 990 shares of the Company’s Series B Convertible Preferred Stock (the “Pr...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Reports Second Quarter 2025 Results
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended June 30, 2025.
Key Highlights
Increased CyPath® Lung revenues 62% year-over-year for the six-month pe...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2025
BIAF
LISTED
NASDAQ
WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
News Preview
JERSEY CITY, N.J., Aug. 13, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer has entered i...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into securities purchase agreements with several institutional and accredited investors (the "Purchasers") for the purchase and sale of 990 shares of th...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge in commercial sales of its flagship product, CyPath® Lung, a noninvasive diagnostic for early-stage lung cancer.
Following a record-setting second quarter, the Company’s...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
BIAF
LISTED
NASDAQ
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today shared another compelling patient case study in which its flagship test, CyPath® Lung, detected pulmonary mucinous adenocarcinoma in a high-risk individual whose previous tests and follow-up scans had s...
Themefolio
Profiler
Peergroup
© BusinessWire
23.07.2025
BIAF
LISTED
NASDAQ
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a compelling new case study in which CyPath® Lung identified a Stage 1A neuroendocrine tumor in the patient’s lung after PET scan, bronchoscopies and a serum tumor...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
BIAF
LISTED
NASDAQ
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the...
Themefolio
Profiler
Peergroup
© BusinessWire
15.07.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a pa...
Themefolio
Profiler
Peergroup
© BusinessWire
09.07.2025
BIAF
LISTED
NASDAQ
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive, accurate tests for the detection of early-stage cancer, today released a new case study of a complex clinical case in which CyPath® Lung identified Stage 1A adenocarcinoma lung cancer in a patient whose PET imaging and risk model prob...
Themefolio
Profiler
Peergroup
© BusinessWire
26.06.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on cancer diagnostics and targeted therapeutics, will present findings today related to the discovery of a potential broad-spectrum cancer therapy that is the subject of the Company’s recently issued U.S. Patent No. 12,305,171 and the notification of patent grant...
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company’s novel composition and method for selectively killing c...
Themefolio
Profiler
Peergroup
© BusinessWire
11.06.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas’ Leadership Boa...
Themefolio
Profiler
Peergroup
© BusinessWire
03.06.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced publication of “The Drive for Early Detection,” a case study detailing how bioAffinity Technologies utilizes support from Cardinal Health™ OptiFreight® Logistics to help meet demand f...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics and targeted therapeutics for cancer, today announced the U.S. Patent and Trademark Office (USPTO) has issued a new patent covering a novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors o...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced the appointment of Gordon Downie, MD, PhD, as its new Chief Medical Officer (CMO). Dr. Downie brings more than three decades of experience in pulmonary medicine,...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Reports First Quarter 2025 Results
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended March 31, 2025.
Key Highlights
Generated revenue of $1.9 million in the first quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
BIAF
LISTED
NASDAQ
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced the release of a white paper authored by Dr. Gordon Downie, MD, PhD, Director of the Lung Nodule Clinic and Interventional Pulmonology at Titus Regional Medi...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2025
BIAF
LISTED
NASDAQ
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering
News Preview
JERSEY CITY, N.J., May 7, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, has closed its prev...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Closing of $3.25 Million Offering
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deduc...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
BIAF
LISTED
NASDAQ
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering
News Preview
JERSEY CITY, N.J., May 6, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, priced a best...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a best efforts offering of securities as described below for aggregate gross proceeds to the Company of $3.25 million, before deducting agent fees and oth...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced implementation of key efficiency measures for its flagship product, CyPath® Lung, the Company’s noninvasive test for detection of lung cancer. These improvem...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024.
2024 Highlights
Record Revenue: Revenue grew approximately 270% to $9.4 mil...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
28.03.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
News Preview
ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 29, at 7 p.m. Eastern Time (ET). Bloomberg TV is a...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
BIAF
LISTED
NASDAQ
Case Study: bioAffinity Technologies’ CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a case study in which a positive CyPath® Lung result led to the detection of a second primary lung cancer in a high-risk patient who was previously diagnosed with stage 1A non-small cell lung cancer and underwent successful surgery in 2023.
“The CyPath® Lung test provided real-ti...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
BIAF
LISTED
NASDAQ
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung microenvironment identified a hidden recurrence of breast cancer in an 80-year-old high-risk patient.
“This case exemplifies how CyPath® Lung can play a crucial role not only in lung cance...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
BIAF
LISTED
NASDAQ
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) announced the release of physicians’ case studies showing the benefit to patients and their doctors of using CyPath® Lung, the Company’s noninvasive test for early detection of lung cancer.
CyPath® Lung’s test result of “Unlikely Lung Cancer” directly prevented a robotic bronchoscopic biopsy or...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced targeted strategic actions to improve financial performance and accelerate the commercial growth of CyPath® Lung, the Company’s noninvasive tes...
Themefolio
Profiler
Peergroup
© PR Newswire
26.02.2025
BIAF
LISTED
NASDAQ
WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
News Preview
JERSEY CITY, N.J., Feb. 26, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited invest...
Themefolio
Profiler
Peergroup
© BusinessWire
26.02.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company’s shares of common stock (the “Existing Warrants”). In consideration for the...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
BIAF
LISTED
NASDAQ
WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
News Preview
JERSEY CITY, N.J., Feb. 25, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding war...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million
News Preview
bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company’s shares of common stock (the “Existing Warrants”). In consideration for the immediate exercis...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Australian Patent Office (IP Australia), has accepted bioAffinity’s patent application for the method of predicting the likelihood of...
Themefolio
Profiler
Peergroup
© BusinessWire
13.01.2025
BIAF
LISTED
NASDAQ
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported the results of the Company’s CyPath® Lung pilot marketing program using Texas for our beta launch with sales of more than 600 tests delivered in 2024.
“We...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
BIAF
LISTED
NASDAQ
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, invites investors to a webinar on Dec. 19, 2024, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature bioAffinity President and CEO Maria Zannes who will share...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
BIAF
LISTED
NASDAQ
bioAffinity Technologies Set for Continued Expansion in 2025
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today reported that the successful execution of its pilot marketing program and steady growth in sales of the CyPath® Lung test for early detection of lung cancers have set the stage for e...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
BIAF
LISTED
NASDAQ
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, will join Federal Supply System (FSS) officials today in a joint presentation highlighting the Veterans Health Administration (VHA) award adding CyPath® Lung to the FSS procurement system...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
BIAF
LISTED
NASDAQ
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2024.
Key Highlights
Generated quarterly revenue of $2.4 million in th...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
BIAF
LISTED
NASDAQ
bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) (“bioAffinity” or the “Company”), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 as Sen...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
BIAF
LISTED
NASDAQ
bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
News Preview
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Japan Patent Office has issued a Certificate of Grant of Patent to bioAffinity Technologies for the method of predicting the likelihoo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
